Gastroprotective Efficacy of Rebamipide in Patients With Atrial Fibrillation Treated With DOACs

The study enrolls 210 patients with atrial fibrillation (AF) and a moderate or high risk of thromboembolic complications (\>=1 point in men and \>=2 points in women according to the CHA2DS2VASc scale), who receives direct oral anticoagulants (DOACs) or has indication to their dministration for prevention of thromboembolic complications and in the same time has indication for gastroprotection. The study includes a screening period (to confirm selection criteria) and a treatment period (maximum 24 weeks), that consists of 4 visits: * Visit 1 (randomization), * Visit 2 and 3 - follow up, * Visit 4 - end of study. Patients will be randomized to one of three treatment groups in a 1:1:1 ratio. * Group Rebamipide, receiving standard therapy and rebamipide 300 mg per day * Group Pantoprazole , receiving standard therapy and pantoprazole 40 mg per day * Group Combination of Rebamipide and Pantoprazole, receiving standard therapy, rebamipide 300 mg per day and pantoprazole 40 mg per day Standard therapy in the study refers to the use of DOAC in accordance with applicable clinical guidelines. Physical examination, blood pressure/heart rate measurement, Adverse Events (AEs) control, concomitant medications and compliance assessment will be performed every visit. An Esophagogastroduodenoscopy (EGD) with H. pylori detection, Lanza score assessment, GOS questionnaire, and laboratory tests (blood and stool tests) will be performed on screening and visit 4.